There was about 1.5 MILLION Shares purchased in last hour of trading, imo. It appeared that someone or several people wanted shares & were not going to be denied. I haven't seen buying like that in EXEL in quite awhile. Sure felt good. I would hate to be short EXEL tonight. Hopefully this is just the beginning !! GL.
And $1.29 is the price they're trying to acquire shares at.
You are just like Chicken Little. You say more or less the same thing all day long; day in and day out. Just like Chicken Little, with that tactic no one trusts your belief. After a couple of the same kind of posts everyone knows you are not in favor of Exel. You have to be an intellectually disabled person. Now quit posting the same dribble repeatedly. You are on ignore.
Many bashers here and without good reason that I can find. I found a setback on one drug "which happens" time to time and this isn't a one trick pony either.
This guy must have found out you here all act like you're from Colorado....
Sentiment: Strong Sell
Never let the facts get in the way of a good story. He's on a roll. Let him go. Just a little more rope....
Sentiment: Strong Sell
Big industry news sends traders and investors scrambling for cannabis stocks. Can CGRW capitalize on this exploding demand and reach $2.50 a share?
" If Exelixis got half of these sales (they will likely get less), that would equate to $2.85 million in revenues annually."
Really thus much? wow...cobiraf will be a highflier and EXEL will participate: in 2016 USD 100m are not utopian.
oh now it has worked!
have you read the new seeking alpha report regarding Exelixis?
In 2007-2011 the melanoma market was $3.4 billion in the U.S, but most of these costs were unrelated to prescription drugs. From the above referenced link, it is unclear what the prescription drug cost percentage was per annum for melanoma treatments, but we do know that for non-melanoma the cost was approximately 3.4% of the total $3.4 billion, or about $115 million. Lets assume this is also true for melanoma. Since only half of melanomas are BRAF mutated, it equates to about $57.5 million in drug sales. At 10% market share $5.7 million in revenues would be split between Roche and Exelixis if my market share estimate holds. If Exelixis got half of these sales (they will likely get less), that would equate to $2.85 million in revenues annually. Again there is a lot of assumptions in this figure and pricing power will be key, so actual revenues could be lower (or higher).
The stock price is down on an up day. There is no meaningful news. The company's latest presentation at Piper Jaffray was awful--I cringed listening to Morrissey pretend to be upbeat while he avoided talking about the 800 elephant in the room ---no leadership or vision...this company just likes to test things that don't work and pays its management much more than they deliver.
Been watching exel for a long time and I have seen this happen many times with this stock. Good news comes out causing smart money to hold down price, cover short position and then begin to go long. Leaving other shorts in the dust. IMO
Sentiment: Strong Buy
Tax selling is especially hard with this stock due to its precipitous fall this year. Some traders harvest their biggest losers (6X) because it results in fewer shares and the tax loss has greater intrinsic value than the shares themselves.Check out the LEAPS going to 2017.
Exel have more than 200 Mil in Cash right now at this poor pps. I wonder hwo sold this at this pps. It´s going to be huge upfront potential right now. Good Luck all Longs.